Brain Advance Access published online on June 23, 2003
Brain, doi:10.1093/brain/awg223
© 2003 by Guarantors of Brain
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
1 Department of Neuroscience, Catholic University, Roma, Italy
* Corresponding author. E-mail: a.evoli{at}rm.unicatt.it.
Received 26 March 2003
; revised 6 May 2003
; accepted 10 May 2003
The term seronegative myasthenia gravis (SNMG) refers to the generalized disease without detectable anti-acetylcholine receptor (anti-AChR) antibodies. In these patients, IgG antibodies against the muscle-specific kinase (MuSK) have been described, which reduced agrin-induced AChR clustering in vitro. We have assayed anti-MuSK antibodies in 78 patients with SNMG, who have been followed for many years in our Institution. Here we describe the clinical phenotype of the 37 patients whose results were positive on this assay. MG with anti-MuSK antibodies was characterized by a striking prevalence of female patients (eight men and 29 women). Age of onset ranged from 6 to 68 years, with 56.8% of patients presenting under 40 years of age. All these patients shared a similar pattern of muscle weakness, with prevalent involvement of cranial and bulbar muscles and a high frequency of respiratory crises; the involvement of limb muscles was comparatively less severe and inconsistent. Single-fibre-EMG confirmed the most sensitive examination in the EMG diagnosis of MuSK-positive disease, while, owing to weakness topography, repetitive nerve stimulation in limb muscles was diagnostic in 56.8% of cases. The effect of edrophonium (or neostigmine) injection was equivocal or negative in 11 of 37 patients (29.7%), and the response to oral pyridostigmine was even more unsatisfactory, ranging from mild benefit to overt intolerance. In thymectomized patients, thymus was normal for age or atrophied, and no benefit from surgery was noticed. Thirty-five of 37 patients were given immunosuppressive therapy and 22 received plasma-exchange. The course of the disease was often characterized by periodic exacerbation phases requiring hospitalization and even assisted ventilation; plasma-exchange produced marked improvement in these cases. At the end of the observation period, most patients, although improved, were still symptomatic, having developed permanent facial and pharyngeal weakness together with some atrophy of facial muscles. MuSK-negative disease was comparatively more heterogeneous. Most patients were affected with mild to moderate symptoms and responded well to pharmacological treatment; however, a few subjects in this group had severe refractory disease, poorly responsive to both acetylcholinesterase inhibitors and immunosuppressants.
Keywords: myasthenia gravis; seronegative myasthenia gravis; MuSK; SF-EMG; plasma exchange
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis
2 Department of General Pathology, Catholic University, Roma, Italy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. P. ter Beek, P. Martinez-Martinez, M. Losen, M. H. de Baets, A. R. Wintzen, J. J.G.M. Verschuuren, E. H. Niks, S. G. van Duinen, A. Vincent, and P. C. Molenaar The Effect of Plasma From Muscle-Specific Tyrosine Kinase Myasthenia Patients on Regenerating Endplates Am. J. Pathol., October 1, 2009; 175(4): 1536 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Pompeo, F. Tacconi, R. Massa, D. Mineo, S. Nahmias, and T. C. Mineo Long-term outcome of thoracoscopic extended thymectomy for nonthymomatous myasthenia gravis Eur. J. Cardiothorac. Surg., July 1, 2009; 36(1): 164 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bartoccioni, F. Scuderi, A. Augugliaro, S. Chiatamone Ranieri, D. Sauchelli, P. Alboino, M. Marino, and A. Evoli HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5 Neurology, January 13, 2009; 72(2): 195 - 197. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ragheb, R. Lisak, R. Lewis, G. Van Stavern, F. Gonzales, and K. Simon A Potential Role for B-Cell Activating Factor in the Pathogenesis of Autoimmune Myasthenia Gravis Arch Neurol, October 1, 2008; 65(10): 1358 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Leite, S. Jacob, S. Viegas, J. Cossins, L. Clover, B. P. Morgan, D. Beeson, N. Willcox, and A. Vincent IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis Brain, July 1, 2008; 131(7): 1940 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-Y. Jeannet, J.-P. Marcoz, T. Kuntzer, and E. Roulet-Perez ISOLATED FACIAL AND BULBAR PARESIS: A PERSISTENT MANIFESTATION OF NEONATAL MYASTHENIA GRAVIS Neurology, January 15, 2008; 70(3): 237 - 238. [Full Text] [PDF]
|
|
|
|
|
|
M. I. Leite, M. Jones, P. Strobel, A. Marx, R. Gold, E. Niks, J. J.G.M. Verschuuren, S. Berrih-Aknin, F. Scaravilli, A. Canelhas, et al. Myasthenia Gravis Thymus: Complement Vulnerability of Epithelial and Myoid Cells, Complement Attack on Them, and Correlations with Autoantibody Status Am. J. Pathol., September 1, 2007; 171(3): 893 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Saulat, P. Maertens, W. J. Hamilton, and B. A. Bassam ANTI-MUSK ANTIBODY AFTER THYMECTOMY IN A PREVIOUSLY SEROPOSITIVE MYASTHENIC CHILD Neurology, August 21, 2007; 69(8): 803 - 804. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Liu, A. M. Garcia, H. Santoro, Y. Zhang, K. McDonnell, J. Dumont, and A. Bitonti Amelioration of Experimental Autoimmune Myasthenia Gravis in Rats by Neonatal FcR Blockade J. Immunol., April 15, 2007; 178(8): 5390 - 5398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H Niks, J. B M Kuks, and J. J G M Verschuuren Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in the Netherlands J. Neurol. Neurosurg. Psychiatry, April 1, 2007; 78(4): 417 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, M. Yang, J. Xu, M. Zhang, B. Lang, W. Wang, and A. Vincent Clinical and serological study of myasthenia gravis in HuBei Province, China J. Neurol. Neurosurg. Psychiatry, April 1, 2007; 78(4): 386 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Deymeer, O. Gungor-Tuncer, V. Yilmaz, Y. Parman, P. Serdaroglu, C. Ozdemir, A. Vincent, and G. Saruhan-Direskeneli Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis Neurology, February 20, 2007; 68(8): 609 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hara, T. Mashima, A. Matsuda, K. Tanaka, M. Tomita, H. Shiraishi, M. Motomura, and M. Nishizawa Vocal cord paralysis in myasthenia gravis with anti-MuSK antibodies Neurology, February 20, 2007; 68(8): 621 - 622. [Full Text] [PDF]
|
|
|
|
|
|
R. Le Panse, G. Cizeron-Clairac, J. Bismuth, and S. Berrih-Aknin Microarrays Reveal Distinct Gene Signatures in the Thymus of Seropositive and Seronegative Myasthenia Gravis Patients and the Role of CC Chemokine Ligand 21 in Thymic Hyperplasia J. Immunol., December 1, 2006; 177(11): 7868 - 7879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. K. Park, S. S. Choi, J. G. Lee, D. J. Kim, and K. Y. Chung Complete stable remission after extended transsternal thymectomy in myasthenia gravis. Eur. J. Cardiothorac. Surg., September 1, 2006; 30(3): 525 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bartoccioni, F. Scuderi, G. M. Minicuci, M. Marino, F. Ciaraffa, and A. Evoli Anti-MuSK antibodies: Correlation with myasthenia gravis severity Neurology, August 8, 2006; 67(3): 505 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Murai, T. Noda, E. Himeno, Y. Kawano, Y. Ohyagi, H. Shiraishi, M. Motomura, and J. Kira Infantile onset myasthenia gravis with MuSK antibodies. Neurology, July 11, 2006; 67(1): 174 - 174. [Full Text] [PDF]
|
|
|
|
|
|
E. H. Niks, J.B.M. Kuks, B. O. Roep, G. W. Haasnoot, W. Verduijn, B. E.P.B. Ballieux, M. H. De Baets, A. Vincent, and J. J.G.M. Verschuuren Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5 Neurology, June 13, 2006; 66(11): 1772 - 1774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Farrugia, M. D. Robson, L. Clover, P. Anslow, J. Newsom-Davis, R. Kennett, D. Hilton-Jones, P. M. Matthews, and A. Vincent MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis Brain, June 1, 2006; 129(6): 1481 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D L H Bennett, K R Mills, P Riordan-Eva, P R J Barnes, and M R Rose Anti-MuSK antibodies in a case of ocular myasthenia gravis J. Neurol. Neurosurg. Psychiatry, April 1, 2006; 77(4): 564 - 565. [Full Text] [PDF]
|
|
|
|
|
|
Y. Hatanaka, S. Hemmi, M. B. Morgan, M. L. Scheufele, G. C. Claussen, G. I. Wolfe, and S. J. Oh Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG Neurology, November 8, 2005; 65(9): 1508 - 1509. [Full Text] [PDF]
|
|
|
|
|
|
E. Saka, M. A. Topcuoglu, B. Akkaya, A. Galati, M. Z. Onal, A. Vincent, A. Evoli, and L. Lauriola Thymus changes in anti-MuSK-positive and -negative myasthenia gravis Neurology, September 13, 2005; 65(5): 782 - 783. [Full Text] [PDF]
|
|
|
|
|
|
M Llabres, F J Molina-Martinez, and F Miralles Dysphagia as the sole manifestation of myasthenia gravis J. Neurol. Neurosurg. Psychiatry, September 1, 2005; 76(9): 1297 - 1300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Lavrnic, M Losen, A Vujic, M De Baets, L J Hajdukovic, V Stojanovic, R Trikic, P Djukic, and S Apostolski The features of myasthenia gravis with autoantibodies to MuSK J. Neurol. Neurosurg. Psychiatry, August 1, 2005; 76(8): 1099 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Caress, C. H. Hunt, and S. D. Batish Anti-MuSK Myasthenia Gravis Presenting With Purely Ocular Findings Arch Neurol, June 1, 2005; 62(6): 1002 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y Nemoto, S Kuwabara, S Misawa, N Kawaguchi, T Hattori, M Takamori, and A Vincent Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis J. Neurol. Neurosurg. Psychiatry, May 1, 2005; 76(5): 714 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Felice, F. J. DiMario, and S. R. Conway Postinfectious Myasthenia Gravis: Report of two Children J Child Neurol, May 1, 2005; 20(5): 441 - 444. [Abstract] [PDF]
|
|
|
|
|
|
L. Lauriola, F. Ranelletti, N. Maggiano, M. Guerriero, C. Punzi, F. Marsili, E. Bartoccioni, and A. Evoli Thymus changes in anti-MuSK-positive and -negative myasthenia gravis Neurology, February 8, 2005; 64(3): 536 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Selcen, T. Fukuda, X.-M. Shen, and A. G. Engel Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology, June 8, 2004; 62(11): 1945 - 1950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Yeh, W.-H. Chen, H.-C. Chiu, and A. Vincent Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese Neurology, June 8, 2004; 62(11): 2131 - 2132. [Full Text] [PDF]
|
|
|
|
|
|
K. Ohta, K. Shigemoto, S. Kubo, N. Maruyama, Y. Abe, N. Ueda, and M. Ohta MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG Neurology, June 8, 2004; 62(11): 2132 - 2133. [Full Text] [PDF]
|
|
|
|
|
|
A. Rostedt and E. Stalberg Joint pain and hyperalgesia due to pyridostigmine bromide in a patient with myasthenia gravis Neurology, March 9, 2004; 62(5): 835 - 836. [Full Text] [PDF]
|
|
|
|
|
|
D. P. Richman and M. A. Agius Treatment of autoimmune myasthenia gravis Neurology, December 23, 2003; 61(12): 1652 - 1661. [Abstract] [Full Text] [PDF]
|
|